In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy.
The current treatment of hereditary hemochromatosis (HH) consists of performing periodic manual whole blood phlebotomies. Erythroapheresis (EPH) is considered to be an alternative procedure if the classic treatment is contra-indicated. A prospective study of 13 consecutive cases of HH were included in a periodic EPH program with the aim of assessing the efficacy, feasibility, and tolerability of EPH in the treatment of HH by induction and maintenance. Iron depletion (ferritin <20 microg/l) was achieved in all patients after a mean of 6.7 +/- 2.9 months of treatment and a mean of 13.5 +/- 7.2 EPH sessions. The procedure was well tolerated and there were no complications. After a follow-up period of 10.5 +/- 6.6 months, only four patients have required further maintenance sessions beyond 6 months after completing the induction therapy. The efficacy, speed, tolerability, and more favorable schedule of an EPH program facilitate treatment of HH.
Muncunill
J
J
Fundació Banc de Sang i Teixits de les Illes Balears, Palma de Mallorca, Spain. jmuncunill@retemail.es
Vaquer
P
P
Galmés
A
A
Obrador
A
A
Parera
M
M
Bargay
J
J
Besalduch
J
J
D000328:Adult; D001781:Blood Component Removal; D017707:Erythrocyte Transfusion; D005240:Feasibility Studies; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D006432:Hemochromatosis / Q000150:complications / Q000151:congenital / Q000628:therapy*; D006801:Humans; D007501:Iron / Q000097:blood*; D008297:Male; D008875:Middle Aged; D018962:Phlebotomy; D011446:Prospective Studies; D012074:Remission Induction; D016896:Treatment Outcome
D005293:Ferritins; D007501:Iron